The fact that depleting UHRF1 or DNMT1 enhances differentiation of THP-1 cells and inhibiting tumor growth in xenograft mice strongly suggest that targeting UHRF1 or DNMT1 might be a novel therapeutic strategy to treat MLL-AF9 AML by inhibiting cellular proliferation and inducing differentiation. Here, MLLT3 is linked to acute myeloid leukemia.